Huntingtin, the protein that when mutated causes Huntington disease (HD), has many known interactors and participates in diverse cellular functions. Mutant Htt (mHtt) engages in a variety of aberrant interactions that lead to pathological gain of toxic functions as well as loss of normal functions. The broad symptomatology of HD, including diminished voluntary motor control, cognitive decline, and psychiatric disturbances, reflects the multifaceted neuropathology. Although currently available therapies for HD focus on symptom management, the autosomal dominant cause and the adult onset make this disease an ideal candidate for genetic intervention. A variety of gene therapy approaches have been tested in mouse models of HD, ranging from those aimed at ameliorating downstream pathology or replacing lost neuronal populations to more upstream strategies to reduce mHtt levels. Here the authors review the results of these preclinical trials.
Huntington disease (HD) is caused by the expansion of a polyglutamine (polyQ) tract in exon 1 of the multifunc tional protein Htt. Affected individuals have more than 36 glutamine repeats, and longer polyQ tracts correlate with earlier onset and increased disease severity (Huntington's Disease Collaborative Research Group 1993) . Expanded polyQ Htt induces degeneration and eventual loss of sus ceptible neuronal populations in the striatum and cortex. Chief among these are striatal medium spiny neurons (MSNs), whose population undergoes an early and severe loss. The deficit in neurons and their processes results in a dramatic atrophy of the putamen and caudate nucleus, as well as cortical thinning (Rosas and others 2008) . HD usually presents in midlife with chorea, dementia, and weight loss, with death typically occurring 15 to 20 years after symptom onset (Walker 2007) . Although the app earance of gross motor deficits or dementia is commonly referred to as disease onset, carriers of expanded polyQ in HD can display psychiatric symptoms such as anxiety, depression and obsessive compulsive disorder, mild cog nitive impairments of episodic memory and executive function, and fine motor deficits years to decades before defined clinical onset (Biglan and others 2009; Duff and others 2007) . Elevated levels of proinflammatory cyto kines are also present in serum at least 16 years prior to motor symptom onset, reflecting the role of inflammation in this disease (Bjorkqvist and others 2008) .
The simple genetic nature and autosomal dominant transmission of HD should facilitate therapy development. Unlike multicause, predominately idiopathic neurodegen erative diseases such as Alzheimer and Parkinson diseases, identification of premanifest mutation carriers and thus presymptomatic treatment initiation is possible for HD. This allows for neuroprotective strategies rather than more complicated restorative methods or techniques for coping with existing neuronal loss. Nonetheless, the therapies currently available to HD patients, which include selec tive serotonin reuptake inhibitors (SSRIs) and atypical antipsychotics for psychiatric disturbances and tetrabena zine for chorea, offer only moderate symptom relief and have no effect on disease progression (De Marchi and others 2001; Huntington Study Group 2006) .
In striking contrast to the simplicity of HD genetics, the convoluted disease mechanisms in this disorder have hindered development of diseasemodifying therapies.
Downstream Targets Neurotrophic Factor Delivery
Neurotrophic factors are secreted growth factors that can enhance differentiation, function, and survival of neurons. Ectopic expression of neurotrophic factors mediated either by viral vectors or the transplantation of genetically modi fied cells has shown some promise in the treatment of mouse models of HD.
Nerve growth factor (NGF) is the prototypical neuro trophin that not only promotes neuronal survival but can also downregulate Htt expression in cultured striatal neurons (Haque and Isacson 2000) . NGF delivery by transplantation of transfected neural stem cells (NSCs) is neuroprotective when administered prior to injec tion of quinolinic acid (QA), an Nmethyldaspartate (NMDA) receptor agonist that induces excitotoxicity and neuropathology similar to that found in HD (Martinez Serrano and Bjorklund 1996) . Transplantation of mes enchymal stem cells (MSCs) genetically engineered to overexpress NGF into the striatum of fourmonthold YAC128 mice (a transgenic model expressing fulllength mHtt) results in moderate improvements in rotarod and clasping behavior but no increase in striatal neuron number or expression of dopamine and cyclicAMP regulated phosphoprotein (DARPP32), a marker of healthy MSNs (Dey and others 2010).
Brainderived neurotrophic factor (BDNF), which is required for differentiation and survival of striatal MSNs, is reduced in the human HD striatum. Expression of BDNF is activated by wtHtt, a function that is lost with polyQ expansion (Zuccato and Cattaneo 2007) . Viral delivery of BDNF to the striatum of rats prior to injection of QA is neuroprotective, resulting in reduced cell loss and lesion volume (Bemelmans and others 1999; Kells and others 2004) . Astrocytes cultured from transgenic mice exp ressing BDNF driven by the glial fibrillary acid protein (GFAP), astrocytespecific promoter, increase their BDNF production in response to inflammatory insults. When grafted into the striatum of nude mice one week or one month before QA injection, these cells produce excess BDNF, which reduces lesion volume and prevents neuro nal death, as measured by NeuN, a marker of neuronal nuclei. This neuroprotection is selective, resulting in increased DARPP32positive MSNs and parvalbumin positive but not choline acetyltransferase-positive inter neurons. In addition, BDNFexpressing astrocyte grafts in unilaterally lesioned animals decrease apomorphine induced rotation, indicating that function is preserved in the protected neurons (Giralt and others 2010) . The ben eficial effects of ectopic BDNF expression have also been demonstrated in the YAC128 transgenic model of HD. In fourmonthold mice, striatal injection of MSCs harvested from mouse femurs and transfected to produce BDNF results in improved clasping and rotarod perfor mance. At 13 months of age, BDNFMSCgrafted mice have displayed more NeuN and DARPP32positive striatal neurons than unmodified MSCgrafted or vehicle injected mice, illustrating the longterm benefit of this treatment (Dey and others 2010) .
Cilliary neurotrophic factor (CNTF), a member of the interleukin (IL)-6 or neuropoietic cytokine family, pro motes the survival of a broad range of neuronal types, including those most susceptible to mHttinduced toxic ity (Ip and Yancopoulos 1996) . Although neuroprotective in QA rat models of HD (De Almeida and others 2001; Emerich and others 1996; Régulier and others 2002) , CNTF has shown no benefit and, in some cases, a detri ment in HD transgenic mice. Lentiviral delivery of CNTF into YAC72 mice results in excellent striatal expression for up to one year following surgery. Although no exacer bation of behavioral deficits is found in treated animals, reduced DARPP32 expression and NeuNpositive cells as well as increased GFAP expression are seen in the striatum of both wildtype and YAC72treated mice (Zala and oth ers 2004) . Moreover, adenoassociated virus (AAV) delivery of CNTF into the striatum of 10weekold R6/1 mice results in earlier onset of rotarod deficits. In addition, this treatment increases body weight loss and reduces exp ression of striatally enriched genes such as DARPP32 and preproenkephalin in both transgenic and wildtype mice (DenovanWright and others 2008). These studies indicate that longterm overexpression of CNTF is not well tolerated, and therefore this neurotrophic factor is not a good candidate for gene therapy in HD.
Glial cell line-derived neurotrophic factor (GDNF) is produced in the developing striatum and is expressed by adult striatal projection neurons as well as interneurons (PérezNavarro and others 2000) . Viral and cellmediated delivery of GDNF prior to QA injection is neuroprotective in rats (Kells and others 2004; PérezNavarro and others 1999; PérezNavarro and others 1996) . Transplantation of NSCs transfected to produce GDNF protects against QA toxicity in nude mice, resulting in moderately reduced loss of NeuNpositive striatal neurons and reduced amphetamine induced rotation (Pineda and others 2006) . When given after symptom onset, lentiviral delivery of GDNF to four to fiveweekold R6/2 mice has no effect on rotarod, clasping, or open field behavior. Intranuclear inclusions, BrdU staining, and neuronal crosssectional area are also unaffected in these animals (Popovic and others 2005) . However, presymptomatic AAVGDNF delivery to five weekold N17182Q transgenic mice significantly delays onset of clasping and rotarod deficits. At 16 weeks of age, compared with untreated mice, the striata of treated mice have decreased inclusions and increased neuronal num ber with larger crosssectional areas, although striatal volume loss is not improved (McBride and others 2006). Moreover, transplantation of GDNFsecreting mouse neural progenitor cells (NPCs) into 60dayold N171 82Q mice following symptom onset results in delayed body weight loss and dramatic improvement in rotarod performance. GDNFNPC transplantation also results in reduced inclusions and increased NeuNpositive cells in the striatum but no improvement in cortical thinning. Although some loss of tyrosine hydroxylase is seen in areas proximal to the graft, no loss of dopaminergic neu rons is observed (Ebert and others 2010) . Thus, GDNF can be a restorative as well as a preventative treatment.
Neuturin (Ntn), a member of the GDNF family, pro motes survival of projection neurons that mediate hypo kinetic movement, making it a logical candidate for the treatment of HD, a disease characterized by hyperkinetic movement (Alberch and others 2002) . Cellmediated deliv ery of Ntn protects projection neurons but not inter neurons in QAlesioned rat striata, which is the opposite effect seen with GDNF overexpression (PérezNavarro and others 2000). This indicates that although these neu rotrophins share expression patterns and receptor family members, they have differential mechanisms of action. As MSNs, the most susceptible neurons in HD, are projection neurons, Ntn may be more suitable for HD gene therapy than GDNF. Viralmediated delivery of Ntn into rats treated with the mitochondrial toxin 3NP is neuroprotective and ameliorates motor deficits (Ramaswamy, McBride, and others 2007) . AAV delivery of Ntn to the striatum of sixweekold N17182Q mice results in increased stride length and delayed rotarod deficits and clasping com pared to AAVGFP or vehicletreated transgenic mice. Treatment with AAVNtn dramatically increases striatal neuron as well as layer 5 and 6 cortical neuron numbers. This therapy, however, has no effect on neuronal cross sectional area, inclusion deposition, or mouse survival (Ramaswamy and others 2008) . Interestingly, inclusion deposition and neuronal crosssectional area are mea sures that are improved by GDNF treatment, indicating that there may be increased benefit of combining these very promising neurotrophic factor gene therapies.
Activation of Endogenous Neural Stem Cells
One approach to coping with neuronal loss is the activa tion of endogenous NSCs in the adult brain. One site of NSCs throughout life is within the subventricular zone (Taupin and Gage 2002) . Delivery of adenoviralBDNF (AdB) into the subventricular zone results in increased NSC proliferation and migration of newly formed cells into the striatum, although the majority of these cells dif ferentiate into glia. Coexpression of noggin, an inhibitor of gliogenesis, pushes these newly generated cells toward a neuronal fate. Intraventricular delivery of BDNF and noggin (AdB/N) into R6/2 mice increases neurogenesis, leading to recruitment of new striatal MSNs, which proj ect axons to their targets. AdB/N gene therapy also results in improved rotarod performance and increased sponta neous activity as well as a 17% increase in survival time (Cho and others 2007) . It is remarkable that the new neu rons "know where to go and what to do when they get there." Because BDNF can stimulate the generation of several other types of neurons, it seems that the local envi ronment in the damaged striatum contains the cues neces sary for MSN differentiation.
Normalization of Calcium Signaling and Mitochondrial Function
volumes, supporting mitochondrial involvement in HD related neurodegeneration (Cui and others 2006) . Mito chondria from HD patient-derived lymphocytes display reduced calciumbuffering capacity, leading to excess cytosolic calcium (Panov and others 2002) . This causes excitotoxicity and aberrant calcium signaling. Calmodulin (CaM), a regulatory protein that associates with mHtt, activates a number of enzymes upon calcium binding. Among these is transglutaminase, an enzyme that catalyzes covalent crosslinking of glutamine residues and possibly contributes to mHttinduced toxicity. Intrastriatal, AAV mediated delivery of a CaM fragment to R6/2 mice dis rupts mHttCaM interaction, leading to a reduction in the level of transglutaminasemodified mHtt. AAVCaM gene therapy also improves rotarod performance, gait, and hypo activity, as well as deposition of inclusions and loss of neuronal size and body weight, although mouse survival is unaffected (Dai and others 2009 ). It will be of interest to determine the effects of this form of gene therapy in fulllength models of HD.
Targeting mHtt Increased Clearance
Considering the multiplicity of pathogenic mechanisms of HD, a more comprehensive, upstream therapeutic app roach is to reduce mHtt protein levels by increasing its degradation. Removal of mHtt is less likely to have dele terious offtarget effects and more likely to ameliorate all aspects of the HD phenotype than are therapies directed at downstream dysfunctions. Interventions that selectively reduce levels of mHtt while sparing the wt protein are preferable because longterm reduction of wtHtt may not be well tolerated. As mentioned at the outset, wtHtt pro tein is important for neuronal health throughout life, and mice with wtHtt conditionally knocked out in adulthood develop progressive motor impairment and neuropathol ogy (Dragatsis and others 2000) . Smallmoleculemediated increases in mHtt clearance have been unsuccessful thus far, ostensibly because of the elaborate and somewhat mysterious mechanisms of endogenous mHtt degradation. On the other hand, gene therapy approaches to selectively increase mHtt clearance have shown considerable promise.
One such approach uses viralmediated delivery of intra bodies (iAbs), which are intracellularly expressed Ab fragments that recognize and bind Htt in living cells. Several antiHtt iAbs have been developed as potential therapeutics, and the most promising of these reduce mHtt induced toxicity by promoting its degradation. EM48 is an iAb that recognizes an epitope in the Cterminus of HDx1. Although this epitope is common to mutant and wtHtt, EM48 preferentially binds mHtt on Western blots, possi bly because of polyQ expansion-induced conformational changes. Observations in a cellular model of HD reveal that EM48 binding increases the ubiquitination and sub sequent degradation of mHtt. Intrastriatal Ad delivery of this iAb into R6/2 and N17182Q mouse models results in increased Htt cleavage and reduced neuropil aggre gates, demonstrating in vivo efficacy of EM48enhanced mHtt degradation. EM48treated N17182Q mice also display improved gait and rotarod performance. However, EM48 gene therapy does not prevent loss of body weight or enhance the survival of these animals (Wang CE and others 2008) .
Another iAb, Happ1, binds the prolinerich region of Htt adjacent to the polyQ tract. Despite its recognition of wtHtt under denaturing conditions, Happ1 binding selec tively increases the turnover of mutant but not wtHtt in cellular models of HD (Southwell and others 2008) . This iAbinduced turnover involves enhanced calpain cleavage of mHtt (Southwell and others 2011) . The target epitope of Happ1 is the site of multiple endogenous protein protein interactions, which are enhanced by polyQ expan sion, suggesting increased epitope availability in the context of mHtt (Passani and others 2000; Qin and others 2004; Steffan and others 2000) . This is likely to be responsible for the selectivity of Happ1 action under native condi tions. Intrastriatal AAV delivery of Happ1 is beneficial in five different mouse models of HD. In a unilateral, acute lentiviralmHtt mouse model, Happ1 treatment prevents the amphetamineinduced rotation phenotype and reduces striatal lesion size and intensity as well as mHtt aggrega tion. In genetic HD models, Happ1 treatment improves rotarod and beamcrossing performance of R6/2, N171 82Q, YAC128, and BACHD mice and spontaneous climbing in YAC128 and BACHD mice. Happ1 treat ment also normalizes openfield exploration in YAC128 and BACHD mice and object learning in YAC128 mice, demonstrating benefit in the psychiatric and cognitive dimensions of the HDlike phenotype. An object learning deficit in BACHD mice is unchanged by Happ1 treat ment, however. Happ1 treatment also improves neuro pathological measures, including ventricular enlargement in R6/2, YAC128, and BACHD mice and inclusion load in R6/2. Importantly, Happ1 gene therapy increases body weight and increases life span by 30% in the N17182Q model ( Fig. 1) , although there is no benefit of Happ1 treat ment in these outcomes in the more severe and earlier onset R6/2 model (Southwell and others 2009) .
The ability of antiHtt iAbs to increase clearance of mHtt and subsequent therapeutic benefit can be improved by fusion to targeting sequences, which direct the degra dation of the bound HttiAb complex. The iAb C4, which recognizes the Nterminus of HDx1, reduces mHttinduced toxicity and aggregation in cell culture, brain slice, and fly models of HD (Lecerf and others 2001; Murphy and Messer 2004; Wolfgang and others 2005) , but AAVmediated C4 gene therapy in R6/1 HD model mice confers only modest phenotypic benefit (SnyderKeller, McLear and others 2010). A fusion protein of this iAb and a PEST signal sequence, a peptide rich in proline, glutamic acid, serine, and threonine, efficiently targets mHtt for proteasomal degradation. C4PEST significantly reduces levels of both soluble and insoluble mHtt in co transfected cultured striatal cells (SnyderKeller, Butler and others 2010). It will be interesting to see how this mod ification affects C4 gene therapy efficacy in HD mice.
A different strategy for reducing mHtt levels involves induction of autophagy. Autophagy is a lysosomal degra dation process for longlived and misfolded cytoplasmic proteins that can selectively degrade mHtt . Chemical induction of autophagy results in accelerated clearance of mHtt and subsequent therapeutic benefit in fly and mouse HD models (Ravikumar and others 2004; Rose and others 2010; Sarkar and others 2008) . Drugmediated global induction of autophagy, how ever, is not specific to Htt and could potentially have off target effects, particularly over the extremely long treatment duration required for HD therapy. The lack of understand ing of the regulation of endogenous, autophagymediated mHtt degradation hampers selective drug development, and therefore there is interest in gene therapy approaches. Specific targeting of mHtt for autophagic degradation has been demonstrated in the R6/2 mouse model by intrastri atal AAVmediated delivery of an expanded polyQ bind ing peptide (QBP1), which binds mutant but not wtHtt. This peptide is fused to a synthetic HSC70 chaperone binding motif (HSC70bm), which targets bound proteins to lysosomes for degradation. Artificial, chaperone mediated, autophagic degradation of mHtt in these animals results in reduced levels of both aggregated and soluble mHtt protein in brain lysates and inclusions in transduced striata. QBP1HSC70bm gene therapy improves clasping and rotarod performance and reduces striatal atrophy. This promising therapy also improves body weight and dramatically increases the survival of this very severe model (Bauer and others 2010) . One would like to see this approach tested in a fulllength mHtt model.
Silencing
The most upstream and direct strategy for the treatment of HD is silencing expression of mHtt mRNA, thus pre venting generation of the toxic protein and all subsequent pathology. At least 10 RNAi gene therapy efficacy pre clinical trials have been performed since 2005, using a variety of rodent models of HD. These studies, recently reviewed by Harper (2009) , are briefly summarized here.
Intrastriatal AAV delivery of a short hairpin RNA (shRNA), HDsh2.1, in N17182Q mice results in reduced inclusions and improved rotarod performance and gait but no change in loss of body weight (Harper and others 2005) . Another shRNA, siHUNT1, which targets the 5′UTR of Htt, delivered by AAV into the striatum of R6/1 mice, reduces inclusions and moderately improves clasping behavior and transcriptional dysregulation but not loss of body weight (RodriguezLebron and others 2005). Postsymptomatic onset, intrastriatal AAV delivery of an shRNA in the HD190QG mouse model causes reduction of inclusion load and a modest restoration of DARPP32 expression (Machida and others 2006) . In an AAVgenerated mouse model of HD, intrastriatal coinjection of mHtt plus cholesterolconjugated small interfering RNA (siRNA), ccsiRNAHtt, reduces inclu sions, improves clasping and beamcrossing performance, 
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The Neuroscientist 17 (2) and ameliorates neuronal loss but not neuronal shrinkage (DiFiglia and others 2007). Adenoviral delivery of an shRNA targeting HDx1 in the striatum of R6/2 mice as well as an AdHDx1 model of HD reduces transgene exp ression and inclusions (Huang and others 2007) . Codelivery of an shRNA, AAVshHD2, along with AAVHDx1, amelio rates loss of NeuN and calbindinpositive cells in the striatum of rats and normalizes asymmetric forepaw use in unilaterally injected animals (Franich and others 2008) . The most positive results to date involve intraventricular delivery of a cholesterolconjugated siRNA targeting HDx1 in neonatal R6/2 mice, resulting in reduced mHDx1 exp ression. Compared to controltreated mice, those receiv ing the HDx1siRNA display reduced inclusions, delayed clasping and loss of body weight, improved rotarod performance and spontaneous activity, reduced striatal atrophy, and an increase in longevity of 14% (Wang YL and others 2005) .
Taken together, the RNAi results appear very promis ing. An important caveat of these studies is, however, that they have all employed speciesspecific RNAi reagents that only target human Htt. As a result, endogenous mouse Htt is not silenced, although it would be in compa rable human HD applications. Some studies have found that nonspecific Htt silencing is relatively nontoxic in mice, resulting in gene expression changes but no overt behavioral phenotype (Boudreau and others 2009; Drouet and others 2009; McBride and others 2008) . Nonspecific silencing has in fact been shown to confer therapeutic benefit in a transgenic mouse model of HD. AAV mediated delivery of miRNA2.4 into the striatum of sevenweekold N17182Q mice results in a 75% reduc tion of both human transgene and mouse endogenous Htt mRNAs. Compared to AAVGFP and vehicletreated mice, miRNAtreated mice display improved rotarod per formance and a trend toward increased survival but no change in loss of body weight (Boudreau and others 2009) . This suggests that nonspecific Htt silencing would be a viable therapeutic option for human HD. The pro longed treatment duration required in humans and the general resistance to Httassociated neurodegeneration in the mouse brain should be considered, however. If sensitiv ity to Httassociated neuropathology were similar between mice and humans, heterozygous knockin HD mice with polyQ lengths equivalent to those seen in patients would model human HD fairly closely. In actuality, these mice have no clear HDrelated phenotype (White and others 1997) , and to model human HD in mice, polyQ expansion lengths well above those seen in humans are used, often in the context of a highly toxic Nterminal fragment. For these reasons, allelespecific mHtt gene silencing that does not disrupt wtHtt expression will be preferable for therapeutic applications.
As the HDcausing mutation is an expansion of a nor mally occurring sequence, development of allelespecific silencing reagents has required ingenuity. Peptide and locked nucleic acid oligonucleotides targeting expanded CAG have shown modest success in selective mHtt silenc ing in cellular models of HD, although selectivity of these reagents declines in the absence of a large repeat length difference between the normal and mutant allele (Hu and others 2009) . Nonetheless, the extremely focused thera peutic mechanism and the potential benefit to not only those afflicted with HD but to those with other CAG expansion diseases warrants further development and optimization of expanded CAGtargeting oligonucleotides. Allelespecific mHtt silencing could also be accomplished by targeting singlenucleotide polymorphisms (SNPs). Many SNPs that are enriched in expanded polyQ human Htt genes have been identified, and silencing reagents tar geting a small number of these diseaseassociated SNPs could provide a therapeutic option for the majority of HD patients (Lombardi and others 2009; Pfister and others 2009; Warby and others 2009) . Development of silenc ing reagents targeting these SNPs is currently under way, and gene therapy efficacy trials in rodent models of HD are eagerly expected in the near future.
Perspectives
It is apparent that a wide variety of gene therapy app roaches display promise for prevention as well as treat ment of HD symptoms. Several of these approaches also have potential application in other polyQ diseases, as well as in other neurodegenerative diseases that involve protein misfolding, such as Parkinson and Alzheimer dis eases and the prionoses. What are the next steps toward human trials? In some cases, the gene therapies must be tested in fulllength HD models. In other cases, the reagents must be optimized for use in humans. There is some debate as to the steps after that. One possibility is to test the reagents in animals with larger brains so as to opti mize delivery of the vectors (Ciron and others 2009; Fiandaca and others 2009; Varenika and others 2009). Another possibility is to test the therapies for efficacy in nonhuman primates. This could be done using lentiviral delivery of mHtt (Palfi and others 2007) . There are also genetic HD models being developed using monkeys, pigs, and sheep (Jacobsen and others 2010; Yang D and others 2010; Yang SH and others 2008) . It will also be extremely important to develop inducible viral vectors so that a transgene that turns out to be ineffective or harmful can be turned off.
Apart from the experimental hurdles that must be overcome, there is a psychological barrier unique to gene therapy in the brain that needs to be confronted. Many researchers believe that inserting genes into the brain is too dangerous and so only smallmolecule approaches should be developed. This view reflects a widespread lack of awareness of the many gene therapy trials that are already ongoing or have been concluded in humans. These include trials of potential treatments for Parkinson and Alzheimer diseases as well as others (Christine and others 2009; Kaplitt and others 2007; Mandel 2010; Marks and others 2008) . In general, such trials have shown that the safety of the surgery and vector delivery is not a cause for great concern, although new methods are still under development. There is also the issue of side effects; direct delivery of vectors into the brain avoids peri pheral side effects, and gene therapies with high target specificity (as with iAbs, for instance) may avoid poten tial side effects of delivering smallmolecule reagents to the periphery.
A daunting reality is that most of the therapies deve loped in mouse models of cancer, for instance, fail in human trials. For that reason alone, it is important that the wide variety of gene therapy approaches summarized here pro ceed in parallel toward human testing.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interests with respect to the authorship and/or publication of this article. 
Financial Disclosure/Funding

